Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today reported financial
results for its first quarter ended March 31, 2020. Provided in
this press release are financial highlights for the quarter,
updates to our financial guidance for the year 2020 and access
information for today’s webcast and conference call.
Tony J. Hunt, President and Chief Executive Officer said, “I’m
really pleased with our flexibility and performance during the
first quarter, while adapting to the challenging economic
environment. We exceeded our financial goals, reporting record
quarterly revenue and organic growth of 16% backed by strong order
demand. The story of the quarter was the continued momentum at gene
therapy accounts and strength in our chromatography and filtration
franchises, with our proteins business performing above
expectations.”
Mr. Hunt added, “The majority of our focus in Q1 and here again
in Q2 is on employee health and safety while working together to
keep our factories and supply chain fully open and operational
during the COVID-19 pandemic. The dedication of our employees
has been remarkable, and I especially want to thank those in our
manufacturing and customer-facing organizations who have helped
deliver on our commitments. While there are clearly uncertainties
as to how the year plays out, we remain optimistic about 2020 as we
execute on our strategy of bringing new products to market, further
developing the gene therapy space and continuing to pace our
investments as we expand our manufacturing capacity.”
Financial Highlights for the First
Quarter 2020
- Revenue increased by 25% year-over-year as reported and 16%
organically, to $76.1 million
- GAAP gross margin increased to 58.0%, a year-over-year increase
of 220 bps
- Adjusted gross margin (non-GAAP) increased to 58.5%, a
year-over-year increase of 250 bps
- GAAP fully diluted EPS increased to $0.18 compared to $0.17 for
the first quarter of 2019
- Adjusted fully diluted EPS (non-GAAP) increased to $0.32
compared to $0.26 for the first quarter of 2019
Financial Details for the First Quarter
2020
REVENUE
- Total revenue for the first quarter of 2020 increased to $76.1
million compared to $60.6 million for the first quarter of 2019, a
year-over-year gain of 25% as reported and 26% at constant
currency, with organic growth of 16%.
GROSS PROFIT and GROSS MARGIN
- Gross profit (GAAP) for the first quarter of 2020 was $44.1
million, a year-over-year increase of $10.3 million and
representing 58.0% gross margin.
- Adjusted gross profit (non-GAAP) for the first quarter of 2020
was $44.5 million, a year-over-year increase of $10.6 million and
representing 58.5% gross margin.
OPERATING INCOME
- Operating income (GAAP) for the first quarter of 2020 was $11.9
million compared to $11.2 million for the first quarter of
2019.
- Adjusted operating income (non-GAAP) for the first quarter of
2020 was $18.3 million, an increase of 18% compared to $15.6
million for the first quarter of 2019.
NET INCOME
- Net income (GAAP) for the first quarter of 2020 was $9.8
million, an increase of 22% compared to $8.1 million for the first
quarter of 2019.
- Adjusted net income (non-GAAP) for the first quarter of 2020
was $16.8 million, an increase of 37% compared to $12.2 million for
the first quarter of 2019.
EARNINGS PER SHARE
- Earnings per share (GAAP) for the first quarter of 2020 were
$0.18 on a fully diluted basis, compared to $0.17 for the first
quarter of 2019.
- Adjusted EPS (non-GAAP) for the first quarter of 2020 were
$0.32 on a fully diluted basis, compared to $0.26 for the 2019
period.
EBITDA
- EBITDA, a non-GAAP financial measure, for the first quarter of
2020 was $18.7 million compared to $15.7 million for the first
quarter of 2019.
- Adjusted EBITDA for the first quarter of 2020 was $21.2
million, an increase of 21% compared to $17.5 million for the first
quarter of 2019.
CASH
- Our cash and cash equivalents at March 31, 2020 were $529.5
million, an increase of $1.1 million from $528.4 million at
December 31, 2019.
All reconciliations of GAAP to adjusted
(non-GAAP) figures above, as well as EBITDA to adjusted EBITDA, are
detailed in the reconciliation tables included later in this press
release.
Financial Guidance for 2020
Our financial guidance for the fiscal year 2020 is based on
expectations for our existing business and includes the financial
impact of our acquisition of C Technologies (which closed on May
31, 2019). The guidance below excludes the impact of potential
additional acquisitions and future fluctuations in foreign currency
exchange rates.
FISCAL YEAR 2020 GUIDANCE:
- We are maintaining our previous guidance for revenue in the
range of $309-$319 million, reflecting overall revenue growth of
14%-18% and organic growth of 10%-14%.
- Gross margin is expected to be 56%-57% on both a GAAP and
non-GAAP basis, an increase from our previous guidance of
55%-56%.
- Income from operations is expected to be in the range of
$52-$56 million on a GAAP basis, an increase from our previous
guidance of $50-$54 million. Adjusted (non-GAAP) income from
operations is expected to be in the range of $72-$76 million, an
increase from our previous guidance of $70-$74 million.
- Net income is expected to be in the range of $34.5-$37.5
million on a GAAP basis, an increase from our previous guidance of
$33.5-$36.5 million. Adjusted (non-GAAP) net income is expected to
be in the range of $58-$61 million, an increase from our previous
guidance of $57-$60 million. Our current guidance reflects a
tax rate of 20% on adjusted pre-tax income, an improvement from our
previous guidance of 23%.
- Fully diluted GAAP EPS is expected to be in the range of
$0.65-$0.70, an increase from our previous guidance of $0.63-$0.68.
Adjusted (non-GAAP) fully diluted EPS is expected to be in the
range of $1.09-$1.14, an increase from our previous guidance of
$1.07-$1.12.
Our non-GAAP guidance for the fiscal year 2020 excludes the
following items:
- $4.7 million estimated acquisition and integration expenses;
$0.5 million in cost of product revenue, $0.5 million in R&D
and $3.7 million in SG&A.
- $15.3 million estimated intangible amortization expense; $0.3
million in cost of product revenue and $15.0 million in
G&A.
- $11.0 million of non-cash interest expense (Other income
(expense)) related to our convertible debt notes.
Our non-GAAP guidance for the fiscal year 2020
includes:
- An income tax expense of $7.4 million, representing the tax
impact of the acquisition and integration of C Technologies,
intangible amortization, and non-cash interest expenses.
All reconciliations of GAAP to adjusted
(non-GAAP) guidance are detailed in the tables included later in
this press release.
Conference CallRepligen will host a conference
call and webcast today, May 6, 2020, at 8:30 a.m. EDT, to discuss
first quarter 2020 financial results and corporate developments.
The conference call will be accessible by dialing toll-free (844)
701-1063 for domestic callers or (412) 317-5487 for international
callers. No passcode is required for the live call. In addition, a
webcast will be accessible via the Investor Relations section of
the Company’s website. Both the conference call and webcast will be
archived for a period of time following the live event. The replay
dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658
from Canada and (412) 317-0088 for international callers. Replay
listeners must provide the passcode 10141587.
Non-GAAP Measures of Financial Performance To
supplement our financial statements, which are presented on the
basis of U.S. generally accepted accounting principles (GAAP), the
following non-GAAP measures of financial performance are included
in this release: revenue growth rate at constant currency, adjusted
gross profit and adjusted gross margin, adjusted income from
operations and adjusted operating margin, earnings before interest,
taxes, depreciation and amortization (EBITDA), adjusted EBITDA,
adjusted net income, adjusted net income per share, adjusted
earnings per diluted share (EPS), adjusted cost of sales, adjusted
research & development expense, adjusted selling, general and
administrative expense, adjusted income tax expense and adjusted
income tax rate. The Company provides organic revenue growth rates
in constant currency to exclude the impact of both foreign currency
translation, and the impact of acquisition revenue for current year
periods that have no prior year comparable, in order to facilitate
a comparison of its current revenue performance to its past revenue
performance. The Company provides revenue growth rates in constant
currency in order to facilitate a comparison of its current revenue
performance to its past revenue performance. To calculate revenue
growth rates in constant currency, the Company converts actual net
sales from local currency to U.S. dollars using constant foreign
currency exchange rates in the current and prior period.
The Company’s non-GAAP financial results and/or non-GAAP
guidance exclude the impact of: acquisition and integration costs
related to the Company’s acquisitions of TangenX Technology
Corporation, Spectrum Lifesciences, LLC (formerly known as
Spectrum, Inc.), and C Technologies Inc.; inventory step-up
charges; intangible amortization costs; non-cash interest expense;
the impact on tax of intangible amortization and acquisition and
integration costs; and, in the case of EBITDA, cash interest
expense related to the Company’s convertible debt. These costs are
excluded because management believes that such expenses do not have
a direct correlation to future business operations, nor do the
resulting charges recorded accurately reflect the performance of
our ongoing operations for the period in which such charges are
recorded.
A reconciliation of GAAP to adjusted non-GAAP financial measures
is included as an attachment to this press release. When analyzing
the Company’s operating performance and guidance investors should
not consider non-GAAP measures as substitutable for the comparable
financial measures prepared in accordance with GAAP.
About Repligen CorporationRepligen Corporation
is a global life sciences company that develops and commercializes
highly innovative bioprocessing technologies and systems that
increase efficiencies in the process of manufacturing biological
drugs. We are inspiring advances in bioprocessing for the customers
we serve; primarily biopharmaceutical drug developers and contract
development and manufacturing organizations (CDMOs) worldwide. Our
corporate headquarters are located in Waltham, MA (USA), and we
have additional administrative and manufacturing operations in
Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Lund,
Sweden; Breda, The Netherlands and Ravensburg, Germany.
The following constitutes a “Safe Harbor” statement under the
Private Securities Litigation Reform Act of 1995: This press
release contains forward-looking statements, which are made
pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Investors are
cautioned that statements in this press release which are not
strictly historical statements, including, without limitation,
express or implied statements or guidance regarding current or
future financial performance and position, including cash and
investment position, demand in the markets in which we operate, the
expected performance of our business, the expected performance of
the C Technologies business, the expected performance and success
of our strategic partnerships, management’s strategy, plans and
objectives for future operations or acquisitions, product
development and sales, selling, general and administrative
expenditures, intellectual property, development and manufacturing
plans, availability of materials and product and adequacy of
capital resources, the projected impact of, and response to, the
COVID-19 pandemic, and financing plans constitute forward-looking
statements identified by words like “believe,” “expect,” “may,”
“will,” “should,” “seek,” “anticipate,” or “could” and similar
expressions. Such forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without
limitation, risks associated with the following: the ultimate
impact of the COVID-19 pandemic on our business or financial
results; our ability to successfully grow our bioprocessing
business, including as a result of acquisition, commercialization
or partnership opportunities; our ability to successfully integrate
any acquisitions, our ability to develop and commercialize products
and the market acceptance of our products; our ability to integrate
the C Technologies business successfully into our business and
achieve the expected benefits of the acquisition; reduced demand
for our products that adversely impacts our future revenues, cash
flows, results of operations and financial condition; our ability
to compete with larger, better financed bioprocessing,
pharmaceutical and biotechnology companies; our compliance with all
U.S. Food and Drug Administration and EMEA regulations; the effect
of the COVID-19 pandemic, including mitigation efforts and economic
effects, on our business operations; our volatile stock price; and
other risks detailed in Repligen’s most recent Annual Report on
Form 10-K on file with the Securities and Exchange Commission and
the other reports that Repligen periodically files with the
Securities and Exchange Commission. Actual results may differ
materially from those Repligen contemplated by these
forward-looking statements. These forward-looking statements
reflect management’s current views and Repligen does not undertake
to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the
date hereof except as required by law.
Repligen Contact: Sondra S. NewmanGlobal
Head of Investor Relations(781) 419-1881investors@repligen.com
|
REPLIGEN CORPORATION |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(Unaudited, amounts in thousands, except share and per
share data) |
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2020 |
|
|
|
2019 |
|
|
|
|
|
|
Revenue: |
|
|
|
|
Product revenue |
|
$ |
76,060 |
|
|
$ |
60,612 |
|
Royalty and other revenue |
|
|
30 |
|
|
|
22 |
|
Total revenue |
|
|
76,090 |
|
|
|
60,634 |
|
Costs and expenses: |
|
|
|
|
Cost of product revenue |
|
|
31,982 |
|
|
|
26,845 |
|
Research and development |
|
|
4,702 |
|
|
|
3,620 |
|
Selling, general and administrative |
|
|
27,500 |
|
|
|
18,998 |
|
|
|
|
64,184 |
|
|
|
49,463 |
|
Income from operations |
|
|
11,906 |
|
|
|
11,171 |
|
Investment income |
|
|
1,364 |
|
|
|
713 |
|
Interest expense |
|
|
(2,976 |
) |
|
|
(1,726 |
) |
Other income, net |
|
|
382 |
|
|
|
358 |
|
Income before income taxes |
|
|
10,676 |
|
|
|
10,516 |
|
Income tax provision |
|
|
861 |
|
|
|
2,463 |
|
Net income |
|
$ |
9,815 |
|
|
$ |
8,053 |
|
Earnings per share: |
|
|
|
|
Basic |
|
$ |
0.19 |
|
|
$ |
0.18 |
|
Diluted |
|
$ |
0.18 |
|
|
$ |
0.17 |
|
Weighted average shares outstanding: |
|
|
|
|
Basic |
|
|
52,138,673 |
|
|
|
43,967,824 |
|
Diluted |
|
|
53,108,847 |
|
|
|
46,279,017 |
|
|
|
|
|
|
|
|
|
|
|
Balance Sheet Data: |
|
March 31,2020 |
|
December 31,2019 |
Cash, cash equivalents and marketable securities |
|
$ |
529,525 |
|
|
$ |
528,392 |
|
Working capital |
|
|
609,525 |
|
|
|
593,515 |
|
Total assets |
|
|
1,406,481 |
|
|
|
1,400,113 |
|
Long-term obligations |
|
|
294,870 |
|
|
|
292,032 |
|
Accumulated earnings |
|
|
15,658 |
|
|
|
5,843 |
|
Stockholders' equity |
|
|
1,069,758 |
|
|
|
1,059,768 |
|
REPLIGEN CORPORATION |
RECONCILIATION OF GAAP INCOME FROM OPERATIONS TO NON-GAAP
(ADJUSTED) INCOME FROM OPERATIONS |
(Unaudited, amounts in thousands) |
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
2020 |
|
|
|
2019 |
|
|
|
|
|
|
|
GAAP INCOME FROM OPERATIONS |
$ |
11,906 |
|
|
$ |
11,171 |
|
|
|
|
|
|
|
ADJUSTMENTS TO INCOME (LOSS) FROM OPERATIONS: |
|
|
|
|
Acquisition and integration costs |
|
|
2,553 |
|
|
|
1,799 |
|
|
Intangible amortization |
|
|
3,878 |
|
|
|
2,611 |
|
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTED INCOME FROM OPERATIONS |
$ |
18,337 |
|
|
$ |
15,581 |
|
|
|
|
|
|
|
|
|
|
|
|
|
REPLIGEN CORPORATION |
RECONCILIATION OF GAAP NET INCOME TO NON-GAAP (ADJUSTED)
NET INCOME |
(Unaudited, amounts in thousands) |
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
2020 |
|
|
|
2019 |
|
|
|
|
|
|
|
GAAP NET INCOME |
$ |
9,815 |
|
|
$ |
8,053 |
|
|
|
|
|
|
|
ADJUSTMENTS TO NET INCOME: |
|
|
|
|
Acquisition and integration costs |
|
|
2,553 |
|
|
|
1,799 |
|
|
Intangible amortization |
|
|
3,878 |
|
|
|
2,611 |
|
|
Non-cash interest expense |
|
|
2,691 |
|
|
|
1,107 |
|
|
Tax effect of intangible amortization and acquisition costs
(1) |
|
|
(2,177 |
) |
|
|
(1,351 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTED NET INCOME |
$ |
16,760 |
|
|
$ |
12,219 |
|
|
|
|
|
|
|
(1) |
Effective as of the quarter ended June 30, 2019, the Company
changed its methodology for calculating its non-GAAP financial
measures to reflect certain tax effects related to acquisition
and integration costs, intangible amortization and non-cash
interest expense. Accordingly, the non-GAAP financial measures for
the three months ended March 31, 2019 have been updated to be
consistent with the methodology used to calculate such measures for
the current period. |
|
|
|
|
|
|
|
REPLIGEN CORPORATION |
RECONCILIATION OF GAAP NET INCOME PER SHARE TO NON-GAAP
(ADJUSTED) NET INCOME PER SHARE |
(Unaudited) |
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
2020 |
|
|
|
2019 |
|
|
|
|
|
|
|
GAAP NET INCOME PER SHARE - DILUTED |
$ |
0.18 |
|
|
$ |
0.17 |
|
|
|
|
|
|
|
ADJUSTMENTS TO NET INCOME PER SHARE - DILUTED: |
|
|
|
|
Acquisition and integration costs |
|
|
0.05 |
|
|
|
0.04 |
|
|
Intangible amortization |
|
|
0.07 |
|
|
|
0.06 |
|
|
Non-cash interest expense |
|
|
0.05 |
|
|
|
0.02 |
|
|
Tax effect of intangible amortization and acquisition costs |
|
|
(0.04 |
) |
|
|
(0.03 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTED NET INCOME PER SHARE - DILUTED |
|
0.32 |
|
|
$ |
0.26 |
|
|
|
|
|
|
|
Totals may not add due to rounding. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPLIGEN CORPORATION |
RECONCILIATION OF GAAP NET INCOME TO ADJUSTED
EBITDA |
(Unaudited, amounts in thousands) |
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
2020 |
|
|
|
2019 |
|
|
|
|
|
|
|
GAAP NET INCOME |
$ |
9,815 |
|
|
$ |
8,053 |
|
|
|
|
|
|
|
ADJUSTMENTS: |
|
|
|
|
Investment Income |
|
|
(1,364 |
) |
|
|
(713 |
) |
|
Interest Expense |
|
|
2,976 |
|
|
|
1,726 |
|
|
Tax Provision |
|
|
861 |
|
|
|
2,463 |
|
|
Depreciation |
|
|
2,485 |
|
|
|
1,575 |
|
|
Amortization(1) |
|
|
3,905 |
|
|
|
2,638 |
|
|
|
|
|
|
|
EBITDA |
|
18,678 |
|
|
|
15,742 |
|
|
|
|
|
|
|
OTHER ADJUSTMENTS: |
|
|
|
|
Acquisition and integration costs |
|
|
2,553 |
|
|
|
1,799 |
|
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTED EBITDA |
$ |
21,231 |
|
|
$ |
17,541 |
|
|
|
|
|
|
|
(1) |
Includes amortization of milestone payments in accordance with GAAP
of $27 for each period presented. |
|
|
|
|
|
|
|
REPLIGEN CORPORATION |
RECONCILIATION OF GAAP COST OF SALES TO NON-GAAP (ADJUSTED)
COST OF SALES |
(Unaudited, amounts in thousands) |
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
2020 |
|
|
|
2019 |
|
|
|
|
|
|
|
GAAP COST OF SALES |
$ |
31,982 |
|
|
$ |
26,845 |
|
|
|
|
|
|
|
ADJUSTMENT TO COST OF SALES: |
|
|
|
|
Acquisition and integration costs |
|
|
(280 |
) |
|
|
(18 |
) |
|
Intangible amortization |
|
|
(127 |
) |
|
|
(134 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTED COST OF SALES |
$ |
31,575 |
|
|
$ |
26,693 |
|
|
|
|
|
|
|
|
|
|
|
|
|
REPLIGEN CORPORATION |
RECONCILIATION OF GAAP R&D EXPENSE TO NON-GAAP
(ADJUSTED) R&D EXPENSE |
(Unaudited, amounts in thousands) |
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
2020 |
|
|
|
2019 |
|
|
|
|
|
|
|
GAAP R&D |
$ |
4,702 |
|
|
$ |
3,620 |
|
|
|
|
|
|
|
ADJUSTMENT TO R&D: |
|
|
|
|
Acquisition and integration costs |
|
|
(282 |
) |
|
|
(27 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTED R&D |
$ |
4,420 |
|
|
$ |
3,593 |
|
|
|
|
|
|
|
|
|
|
|
|
|
REPLIGEN CORPORATION |
RECONCILIATION OF GAAP SG&A EXPENSE TO NON-GAAP
(ADJUSTED) SG&A EXPENSE |
(Unaudited, amounts in thousands) |
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
|
2020 |
|
|
|
2019 |
|
|
|
|
|
|
|
GAAP SG&A EXPENSE |
$ |
27,500 |
|
|
$ |
18,998 |
|
|
|
|
|
|
|
ADJUSTMENTS TO SG&A EXPENSE: |
|
|
|
|
Acquisition and integration costs |
|
|
(1,990 |
) |
|
|
(1,753 |
) |
|
Intangible amortization |
|
|
(3,751 |
) |
|
|
(2,474 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
ADJUSTED SG&A EXPENSE |
$ |
21,759 |
|
|
$ |
14,771 |
|
REPLIGEN CORPORATION |
RECONCILIATION OF GAAP NET INCOME GUIDANCE TO ADJUSTED
(NON-GAAP NET INCOME GUIDANCE) |
|
|
|
|
|
|
(in thousands) |
Twelve months ending December 31, 2020 |
|
|
|
Low End |
|
High End |
GUIDANCE ON NET INCOME |
$ |
34,500 |
|
|
$ |
37,500 |
|
ADJUSTMENTS TO GUIDANCE ON NET INCOME: |
|
|
|
|
Acquisition and integration costs |
|
|
4,659 |
|
|
|
4,659 |
|
|
Anticipated pre-tax amortization of |
|
|
|
|
|
acquisition-related intangible assets |
|
|
15,251 |
|
|
|
15,251 |
|
|
Non-cash interest expense |
|
|
10,960 |
|
|
|
10,960 |
|
|
Tax effect of intangible amortization and integration |
|
|
(7,360 |
) |
|
|
(7,360 |
) |
|
Guidance rounding adjustment |
|
|
(10 |
) |
|
|
(10 |
) |
GUIDANCE ON ADJUSTED NET INCOME |
$ |
58,000 |
|
|
$ |
61,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
REPLIGEN CORPORATION |
RECONCILIATION OF GAAP NET INCOME PER SHARE GUIDANCE
TO |
ADJUSTED (NON-GAAP) NET INCOME PER SHARE
GUIDANCE |
|
|
|
|
|
|
|
|
|
Twelve months ending December 31, 2020 |
|
|
|
Low End |
|
High End |
GUIDANCE ON NET INCOME PER SHARE - DILUTED |
$ |
0.65 |
|
|
$ |
0.70 |
|
ADJUSTMENTS TO GUIDANCE ON NET INCOME PER SHARE - DILUTED: |
|
|
|
Acquisition and integration costs |
|
$ |
0.09 |
|
|
$ |
0.09 |
|
|
Anticipated pre-tax amortization of |
|
|
|
|
|
acquisition-related intangible assets |
|
$ |
0.29 |
|
|
$ |
0.29 |
|
|
Non-cash interest expense |
|
$ |
0.21 |
|
|
$ |
0.21 |
|
|
Tax effect of intangible amortization and integration |
|
($ |
0.14 |
) |
|
($ |
0.14 |
) |
|
Guidance rounding adjustment |
|
($ |
0.00 |
) |
|
($ |
0.00 |
) |
GUIDANCE ON ADJUSTED NET INCOME PER SHARE - DILUTED |
$ |
1.09 |
|
|
$ |
1.14 |
|
|
|
|
|
|
|
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024